Jenburkt Pharmaceuticals Intrinsic Value
JENBURPH • Healthcare
Current Stock Price
₹1012.95
Primary Intrinsic Value
₹1617.00
Market Cap
₹405.2 Cr
-14.6%
Downside
Median Value
₹865.00
Value Range
₹641 - ₹1617
Assessment
Trading Above Median Value
Safety Margin
-17.1%
JENBURPH Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1617.00 | ₹1293.60 - ₹1940.40 | +59.6% | EPS: ₹73.50, Sector P/E: 22x |
| Book Value Method | asset | ₹860.00 | ₹774.00 - ₹946.00 | -15.1% | Book Value/Share: ₹430.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹865.00 | ₹778.50 - ₹951.50 | -14.6% | Revenue/Share: ₹432.50, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1200.00 | ₹1080.00 - ₹1320.00 | +18.5% | EBITDA: ₹48.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹752.02 | ₹601.62 - ₹902.42 | -25.8% | CF Growth: 8.8%, Discount: 15% |
| PEG Ratio Method | growth | ₹641.31 | ₹577.18 - ₹705.44 | -36.7% | EPS Growth: 10.9%, Fair P/E: 8.7x |
| Growth Adjusted P/E | growth | ₹1144.47 | ₹1030.02 - ₹1258.92 | +13.0% | Revenue Growth: 7.6%, Adj P/E: 15.6x |
| ROE Based Valuation | profitability | ₹1120.00 | ₹1008.00 - ₹1232.00 | +10.6% | ROE: 18.6%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹843.27 | ₹758.94 - ₹927.60 | -16.8% | EPS: ₹73.50, BVPS: ₹430.00 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
JENBURPH Intrinsic Value Analysis
What is the intrinsic value of JENBURPH?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Jenburkt Pharmaceuticals (JENBURPH) is ₹865.00 (median value). With the current market price of ₹1012.95, this represents a -14.6% variance from our estimated fair value.
The valuation range spans from ₹641.31 to ₹1617.00, indicating ₹641.31 - ₹1617.00.
Is JENBURPH undervalued or overvalued?
Based on our multi-method analysis, Jenburkt Pharmaceuticals (JENBURPH) appears to be trading above median value by approximately 14.6%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 9.50 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 18.6% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 24.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.88x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Jenburkt Pharmaceuticals
Additional stock information and data for JENBURPH
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹28 Cr | ₹20 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹8 Cr | ₹8 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹17 Cr | ₹17 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹9 Cr | ₹9 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹20 Cr | ₹11 Cr | Positive Free Cash Flow | 8/10 |